BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)

Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.

05/14/2026, 1:49 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Sila Realty Trust's sale to Blue Owl affiliates, Esperion Therapeutics' sale to ARCHIMED funds, and a merger between Corebridge Financial and Equitable Holdings. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

05/06/2026, 9:41 PM • GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)

Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisition at $30.38/share), Lisata Therapeutics (Kuva Labs acquisition at $4.00/share plus CVRs), and SkyWater Technology (IonQ acquisition at $35.00/share).

05/05/2026, 2:56 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating Sila Realty Trust's $30.38 per share sale to Blue Owl Real Estate Capital affiliates and Lisata Therapeutics' $4.00 per share sale to Kuva Labs. The firm is examining potential securities law violations and breaches of fiduciary duties, seeking to determine if shareholders are receiving fair consideration and if insider benefits are being prioritized over ordinary shareholder interests.

05/04/2026, 2:48 PM • GlobeNewswire

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA

Class action law firm Monteverde & Associates PC announced investigations into several merger and acquisition transactions, including Lisata Therapeutics' sale to Smithfield Foods, Independent Bank Corporation's merger with HCB Financial Corp, and Sila Realty Trust's sale to Sunshine Ultimate Parent LLC. The firm is seeking shareholders who may have concerns about these proposed deals.

05/04/2026, 1:45 PM • GlobeNewswire

Sila Realty Trust Agrees To Buyout At 19% Market Premium

Sila Realty Trust has agreed to be acquired by Blue Owl Capital Inc. affiliates in a $2.4 billion deal at $30.38 per share, representing a 19% premium to the closing price on April 17, 2026. The acquisition is unanimously approved by Sila's board and expected to close in Q2 or Q3 2026, pending shareholder approval. Post-closure, Sila will delist from the NYSE.

04/20/2026, 2:18 PM • Benzinga

RegEd Honored with Multiple SILA Award Nominations, Showcasing Industry Leadership in Licensing and Compliance

RegEd received multiple nominations from the Securities & Insurance Licensing Association (SILA), including two individual nominations for compliance experts and an Organization of the Year Award nomination, highlighting the company's leadership in insurance and securities compliance technology.

10/15/2025, 1:00 PM • GlobeNewswire

Healthcare Is Sickly but These Dividend Yields up to 7% May Still Have a Pulse

Healthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges.

08/29/2025, 5:14 AM • Investing